CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
5.44
-0.02 (-0.37%)
At close: Aug 8, 2025, 4:00 PM
5.43
-0.01 (-0.18%)
After-hours: Aug 8, 2025, 6:29 PM EDT
Qualtrics International Revenue
CureVac had revenue of 893.00K EUR in the quarter ending March 31, 2025, a decrease of -92.78%. This brings the company's revenue in the last twelve months to 523.70M, up 787.60% year-over-year. In the year 2024, CureVac had annual revenue of 535.18M with 895.54% growth.
Revenue (ttm)
523.70M EUR
Revenue Growth
+787.60%
P/S Ratio
2.16
Revenue / Employee
532,757 EUR
Employees
983
Market Cap
1.22B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 535.18M | 481.42M | 895.54% |
| Dec 31, 2023 | 53.76M | -13.66M | -20.26% |
| Dec 31, 2022 | 67.42M | -35.57M | -34.54% |
| Dec 31, 2021 | 102.99M | 54.12M | 110.74% |
| Dec 31, 2020 | 48.87M | 31.46M | 180.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CVAC News
- 2 days ago - CureVac settles patent dispute litigation with Pfizer and BioNTech - Reuters
- 6 weeks ago - CureVac Announces Voting Results of General Meeting - Accesswire
- 2 months ago - Top Stock Movers Now: Oracle, Boeing, CureVac, and More - Investopedia
- 2 months ago - BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
- 2 months ago - BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising. - Barrons
- 2 months ago - BioNTech to acquire CureVac in $1.25 billion all-stock deal - Reuters
- 2 months ago - CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - Accesswire
- 3 months ago - CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE - Accesswire